C3 GLOMERULOPATHY
Clinical trials for C3 GLOMERULOPATHY explained in plain language.
Never miss a new study
Get alerted when new C3 GLOMERULOPATHY trials appear
Sign up with your email to follow new studies for C3 GLOMERULOPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug shows promise for Post-Transplant kidney disease recurrence
Disease control CompletedThis study tested a drug called pegcetacoplan in 13 people whose rare kidney diseases (C3G or IC-MPGN) returned after a kidney transplant. The goal was to see if the drug could reduce signs of disease in the kidney and was safe. Participants received the drug or standard care, an…
Matched conditions: C3 GLOMERULOPATHY
Phase: PHASE2 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 26, 2026 11:07 UTC
-
Hope for rare kidney patients: new drug shows promise in phase 3 trial
Disease control CompletedThis study tested a drug called pegcetacoplan in 124 adults and teens with two rare kidney diseases (C3G and IC-MPGN). The goal was to see if the drug could reduce protein in the urine, a sign of kidney damage, compared to a placebo. Participants received injections twice a week …
Matched conditions: C3 GLOMERULOPATHY
Phase: PHASE3 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New drug targets kidney disease in early trial
Disease control CompletedThis study tested a new drug called ARO-C3 in healthy volunteers and people with kidney diseases caused by an overactive immune system (C3 Glomerulopathy and IgA Nephropathy). The main goal was to check the drug's safety and how it moves through the body. Participants received on…
Matched conditions: C3 GLOMERULOPATHY
Phase: PHASE1, PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated May 18, 2026 12:12 UTC